| Identification |
| Name: | 1H-Pyrrole-1-heptanoicacid, 2-(4-fluorophenyl)-b,d-dihydroxy-4-[[(4-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-,(bR,dR)- |
| Synonyms: | BMS241423-01; PD 142542; p-Hydroxyatorvastatin |
| CAS: | 214217-88-6 |
| Molecular Formula: | C33H35 F N2 O6 |
| Molecular Weight: | 1197.4 |
| InChI: | InChI=1/C33H35FN2O6.2Na/c1-20(2)31-30(33(42)35-24-12-14-25(37)15-13-24)29(21-6-4-3-5-7-21)32(22-8-10-23(34)11-9-22)36(31)17-16-26(38)18-27(39)19-28(40)41;;/h3-15,20,26-27,37-39H,16-19H2,1-2H3,(H,35,42)(H,40,41);;/q;2*+1/p-2/t26-,27-;;/m1../s1 |
| Molecular Structure: |
 |
| Properties |
| Usage: | A metabolite of Atorvastin, a selective, competitive HMG-CoA reductase inhibitor. Atorvastin is the only drug in its class specfically indicated for lowering both elevated LDL-cholesterol and triglycerides in patients with hypercholesterolemia |
| Safety Data |
| |
 |
